Search Results

The company highlights the critical role of unified digital platforms in ensuring compliance, sponsor trust, and clinical readiness.

Highlights ● Insilico published a new study unveiling Target Identification Pro (TargetPro), a superior disease-specific model, and TargetBench 1.0, the first standardized benchmarking framework for target discovery. ● TargetPro achieved 71.6% retrieval of known clinical targets, a 2–3x improvement over large language models (LLMs) such as GPT-4o, Grok3, DeepSeek-R1, Claude-Opus-4, BioGPT, and public platforms like Open Targets. ● TargetPro’s predicted novel targets demonstrated 95.7% structure availability, 86.5% druggability, and 46% repurposing potential, outperforming competing systems on all measures. ● TargetBench’s explainable AI models revealed disease-specific feature importance patterns, emphasizing the value of disease-specific target identification models. ● New gold standard approaches improve accuracy, reliability, and transparency in AI-driven drug discovery.

Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.

Jeanne Marrazzo, former director of the National Institutes of Allergy and Infectious Disease, was formally terminated Thursday after months on administrative leave, after filing a whistleblower report.

Expanded exemptions for orphan drugs could mean prolonged protections for top-selling drugs like Merck’s Keytruda, which was initially approved under this designation in 2014.